We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Mavupharma

News List

AbbVie acquires STING pathway-focused Mavupharma pharmaceutical-technology
July 17, 2019
Chicago-based AbbVie has announced its acquisition of Seattle-based oncology drug discovery company Mavupharma. The financial terms of the transaction were not disclosed.
AbbVie Acquires Mavupharma americanpharmaceuticalreview
July 17, 2019
AbbVie has acquired Seattle-based Mavupharma, a privately held biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway for the treatment of cancer.
Frazier-Backed Mavupharma Scores $20M to Fund STING Program biospace
November 30, 2017
Frazier-backed Mavupharma secures $20M in Series A financing to fund STING program